CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
(Source: ClinicoEconomics and Outcomes Research)
Source: ClinicoEconomics and Outcomes Research - February 17, 2023 Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research
Antidiabetic drug sitagliptin blocks cyclophosphamide cerebral neurotoxicity by activating Nrf2 and suppressing redox cycle imbalance, inflammatory iNOS/NO/NF- κB response and caspase-3/Bax activation in rats
Int Immunopharmacol. 2023 Feb 10;116:109816. doi: 10.1016/j.intimp.2023.109816. Online ahead of print.ABSTRACTCyclophosphamide (CYP) is a classic DNA-interacting anticancer agent with broad application in chemotherapy. However, CYP cerebral neurotoxicity is a worrisome side effect for clinicians and patients. Strategies to mitigate the underlying oxidative inflammatory cascades and neuroapoptosis induced by CYP are urgently needed. Herein, we have repurposed an antidiabetic drug, sitagliptin (STG), for a possible abrogation of CYP-induced cerebral neurotoxicity in rats. Healthy rats were administered STG (20 mg/kg body wei...
Source: International Immunopharmacology - February 12, 2023 Category: Allergy & Immunology Authors: Ademola C Famurewa Nnaemeka T Asogwa Samson C Ezea Source Type: research
Antidiabetic drug sitagliptin blocks cyclophosphamide cerebral neurotoxicity by activating Nrf2 and suppressing redox cycle imbalance, inflammatory iNOS/NO/NF- κB response and caspase-3/Bax activation in rats
Int Immunopharmacol. 2023 Feb 10;116:109816. doi: 10.1016/j.intimp.2023.109816. Online ahead of print.ABSTRACTCyclophosphamide (CYP) is a classic DNA-interacting anticancer agent with broad application in chemotherapy. However, CYP cerebral neurotoxicity is a worrisome side effect for clinicians and patients. Strategies to mitigate the underlying oxidative inflammatory cascades and neuroapoptosis induced by CYP are urgently needed. Herein, we have repurposed an antidiabetic drug, sitagliptin (STG), for a possible abrogation of CYP-induced cerebral neurotoxicity in rats. Healthy rats were administered STG (20 mg/kg body wei...
Source: International Immunopharmacology - February 12, 2023 Category: Allergy & Immunology Authors: Ademola C Famurewa Nnaemeka T Asogwa Samson C Ezea Source Type: research
Sitagliptin Ameliorates Creb5/lncRNA ENSMUST00000213271-Mediated Vascular Endothelial Dysfunction in Obese Mice
ConclusionCreb5/lncRNA ENSMUST00000213271 mediated vascular endothelial dysfunction through inhibiting AMPK/eNOS cascade in obesity. Elevation of GLP-1 by sitagliptin possibly improved endothelial function by suppressingCreb5/lncRNA ENSMUST00000213271 and subsequently restoring AMPK/eNOS activation in obese mice. This study will provide new evidence for the benefits of GLP-1 against vasculopathy in obesity. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - February 4, 2023 Category: Cardiology Source Type: research
DPP4 Inhibitor Sitagliptin Reduces Inflammatory Responses and Mast Cell Activation in Allergic Rhinitis
Conclusion: Sitagliptin suppresses the effector phase of AR, and this mechanism is partly attributed to the suppression of inflammatory response and mast cell degranulation.Pharmacology (Source: Pharmacology)
Source: Pharmacology - February 1, 2023 Category: Drugs & Pharmacology Source Type: research
